TABLE 2.

Summary of meta-analysis.

Outcomes	Subgroup	No. of studies	No. of participants	Effect size (95% CI)	p
28-day mortality	non-English	10	698	RR, 0.74 (0.54, 1.02)	0.06
	English	3	823	RR, 1.03 (0.79, 1.34)	0.83
	Overall	13	1,521	RR, 0.97 (0.83, 1.13)	0.70
	Low score	9	596	RR, 0.72 (0.52, 1.00)	0.05
	High score	4	925	RR, 1.04 (0.83, 1.29)	0.73
	Overall	13	1,521	RR, 0.97 (0.83, 1.13)	0.70
	High dose	4	260	RR, 0.65 (0.34, 1.23)	0.18
	Low dose	9	1,261	RR, 1.01 (0.87, 1.17)	0.92
	Overall	12	1,521	RR, 0.97 (0.83, 1.13)	0.70
ICU stays	NA	10	966	SMD, -0.16 (-0.29, -0.02)	0.03
Duration of mechanical ventilation	NA	6	345	SMD, −0.22 (−0.44, −0.01)	0.043
Incidence of adverse events	NA	7	889	RR, 0.64 (0.37, 1.11)	0.11
SOFA	NA	3	225	SMD, −0.41 (-0.73, -0.09)	0.013
Levels of IL-6 at 24 h	NA	3	191	SMD, −2.53 (−5.30, 0.24)	0.074
Levels of CK-MB at 72 h	NA	3	420	SMD, −0.45 (−0.83, −0.08)	0.017

Note: SOFA, sequential organ failure assessment; RR, relative risks; WMD, weighted mean difference.